10x Genomics affiliate proposes $453K share sale

The reported date for plan adoption or instruction, if relying on Rule 10b5-1, is March 13, 2026.

Available on EDGAR 09/22/2026 - 06:28 PM EDT Accepted by SEC EDGAR 09/22/2026 - 06:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) affiliate Shehnaaz Suliman is listed for a proposed sale of 5,723 Class A Common shares, with an aggregate market value of $452,689.20 and an approximate sale date of September 22, 2026. JP Morgan Securities LLC is listed as the broker.

Shehnaaz Suliman is also listed as having sold 5,723 Class A Common shares on August 24, 2026, for gross proceeds of $140,477.91. The shares listed for the proposed sale were acquired through RSU vesting as compensation on August 21, 2024.

Key Figures

Proposed shares to be sold: 5,723 Class A Common shares Aggregate Market Value: $452,689.20 Shares sold during the past three months: 5,723 Class A Common shares +1 more

4 metrics

Proposed shares to be sold 5,723 Class A Common shares Approximate sale date September 22, 2026

Aggregate Market Value $452,689.20 Proposed sale of 5,723 Class A Common shares

Shares sold during the past three months 5,723 Class A Common shares Sale on August 24, 2026

Gross Proceeds $140,477.91 Sale on August 24, 2026

Key Terms

RSU Vesting, Rule 10b5-1, Aggregate Market Value, Gross Proceeds

4 terms

RSU Vesting technical

"Nature of Acquisition Transaction: RSU Vesting"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

Rule 10b5-1 regulatory

"If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Gross Proceeds financial

"Gross Proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TXG shares is Shehnaaz Suliman planning to sell?

Shehnaaz Suliman is listed for a proposed sale of 5,723 Class A Common shares, with an aggregate market value of $452,689.20 and an approximate sale date of September 22, 2026. JP Morgan Securities LLC is listed as the broker.

How many TXG shares did Shehnaaz Suliman sell, and for how much?

Shehnaaz Suliman is listed as having sold 5,723 Class A Common shares on August 24, 2026, for gross proceeds of $140,477.91.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001713070
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	10X Genomics, Inc.
SEC File Number	001-39035
Address of Issuer	6230 Stoneridge Mall Road Pleasanton CALIFORNIA 94588
Phone	925-401-7300
Name of Person for Whose Account the Securities are To Be Sold	Shehnaaz Suliman
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	JP Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	5723	452689.2	120212296	09/22/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	08/21/2024	RSU Vesting	Issuer			5723	08/21/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shehnaaz Suliman Care of TXG Genomics Inc 6230 Stoneridge Mall Road Pleasanton CA 94588	Class A Common	08/24/2026	5723	140477.91

144: Remarks and Signature

Remarks	The shares represented on this filing were acquired via RSU award between 08/21/24 and 05/21/25.
Date of Notice	09/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Shehnaaz Suliman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)